GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL157 processing
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Dec 31, 2016

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-17-000020Insurance
Cash56thOwn-history percentile · N=16
Evidence method

Level · gp.fundamentals.cash

$791.3M · CORE · VALID

Policy-benefit growth50thOwn-history percentile · N=12
Evidence method

Yoy · gp.insurance.policy_benefits

15.45% · OPTIONAL · VALID

Net-income growth45thOwn-history percentile · N=11
Evidence method

Yoy · gp.fundamentals.net_income

-62.13% · CORE · VALID

Premium growth50thOwn-history percentile · N=12
Evidence method

Yoy · gp.insurance.premiums

21.41% · CORE · VALID

Revenue growth75thOwn-history percentile · N=12
Evidence method

Yoy · gp.fundamentals.revenue

46.17% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Decreased
Previous
$812.8M
Current
$791.3M
Delta
-$21.5M
Claims Growth Decreased
Previous
37.47%
Current
15.45%
Delta
-22.01%
Earnings Growth Increased
Previous
-107.63%
Current
-62.13%
Delta
45.49%
Premium Growth Decreased
Previous
52.74%
Current
21.41%
Delta
-31.33%
Revenue Growth Decreased
Previous
396.25%
Current
46.17%
Delta
-350.07%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.